- We will send in 10–14 business days.
/images/books/13454896/9783954893591.jpg)
- Author: Sara Schlenkrich
- Publisher: Anchor Academic Publishing
- ISBN-10: 3954893592
- ISBN-13: 9783954893591
- Format: 14.8 x 21 x 0.4 cm, softcover
- Language: English
- SAVE -10% with code: EXTRA
The Act on the Reform of the Market for Medicinal Products (AMNOG) (e-book) (used book) | bookbook.eu
Reviews
Description
In the past, high costs have been incurred in particular by the market launch of new medicinal products. To date, it was not necessary to demonstrate an additional therapeutic benefit. This changed with the Act on the Reform of the Market for Medicinal Products (AMNOG), which entered into force on the 1st of January 2011. It brought about a fundamental change in the balance of power on the pharmaceutical market. This study therefore sets out to answer the following question: What impact does the early benefit assessment in the context of the AMNOG have on the stakeholders of the healthcare system? To answer this question, this survey first presents the theoretical foundations of the law, of the early benefit assessment and the bodies involved. It then takes stock of the decisions taken to date before describing the impact on the selected stakeholders.
EXTRA 10 % discount with code: EXTRA
The promotion ends in 19d.06:33:57
The discount code is valid when purchasing from 10 €. Discounts do not stack.
- Author: Sara Schlenkrich
- Publisher: Anchor Academic Publishing
- ISBN-10: 3954893592
- ISBN-13: 9783954893591
- Format: 14.8 x 21 x 0.4 cm, softcover
- Language: English English
In the past, high costs have been incurred in particular by the market launch of new medicinal products. To date, it was not necessary to demonstrate an additional therapeutic benefit. This changed with the Act on the Reform of the Market for Medicinal Products (AMNOG), which entered into force on the 1st of January 2011. It brought about a fundamental change in the balance of power on the pharmaceutical market. This study therefore sets out to answer the following question: What impact does the early benefit assessment in the context of the AMNOG have on the stakeholders of the healthcare system? To answer this question, this survey first presents the theoretical foundations of the law, of the early benefit assessment and the bodies involved. It then takes stock of the decisions taken to date before describing the impact on the selected stakeholders.
Reviews